glp-1 weight loss rate The Access Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss Drugs GLP-1 Agonists In Obesity

1314, Jan

Intra EAA+ Lean muscle support

doi: 10.3389/fendo.2024.1431292 Received 11 May 2024 Accepted 08 July 2024 Published 24 July 2024 Volume 15 - 2024 Edited by Hisamitsu Ishihara, Nihon University, Japan Reviewed by Alessandro Pocai, Janssen Research and Development, United States Hiroshi Nomoto, Hokkaido University Hospital, Japan Updates Copyright 2024 Liu

Results vary depending on individual health conditions, medication response, and lifestyle changes

Furthermore, device use within the GLP-1 using population declined only slightly, so that the overall impact on device use was less than 1%: While GLP-1s have been available for over 20 years, what has captured analysts attention over the past quarter are the dramatic increases in the percentage of body weight lost

After 24 weeks, all groups taking retatrutide saw significant weight loss compared to the placebo group (1.6% average weight loss): 7.2% for those taking 1 mg 11.8% for those taking 4 mg after starting with 2 mg 13.9% for those taking 4 mg after starting with 4 mg 16.7% for those taking 8 mg after starting with 2 mg 17.9% for those taking 8 mg after starting with 4 mg 17.5% for those taking 12 mg after starting with 2 mg After 48 weeks, patients taking retatrutide experienced even more substantial losses: 8.7% for those taking 1 mg 16.3% for those taking 4 mg after starting with 2 mg 17.8% for those taking 4 mg after starting with 4 mg 21.7% for those taking 8 mg after starting with 2 mg 23.9% for those taking 8 mg after starting with 4 mg 24.2% for those taking 12 mg after starting with 2 mg The researchers also reported that 100% of patients taking 8 mg or 12 mg saw a weight reduction of at least 5%, and 7583% had a weight reduction of 15% or more